Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy in Treating Patients With Colon Cancer
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), November 2002
First Received: October 3, 2002   Last Updated: February 6, 2009   History of Changes
Sponsored by: Groupe Regional d'Etudes du Cancer Colorectal
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00046995
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which schedule of chemotherapy is most effective in treating colon cancer.

PURPOSE: Randomized phase III trial to compare different schedules of chemotherapy using carboplatin with fluorouracil and leucovorin in treating patients who have stage IIB or stage III colon cancer.


Condition Intervention Phase
Colorectal Cancer
 Drug: carboplatin
Drug: fluorouracil
Drug: leucovorin calcium
Procedure: adjuvant therapy
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Official Title: 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).

Resource links provided by NLM:

MedlinePlus related topics: Cancer Colorectal Cancer
Drug Information available for: Fluorouracil Leucovorin Carboplatin Citrovorum factor Leucovorin Calcium Folinic acid calcium salt pentahydrate
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Disease-free survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tolerability [ Designated as safety issue: Yes ]
  • Quality of life [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: May 2001
Detailed Description:

OBJECTIVES:

  • Compare the disease-free survival of patients with completely resected stage IIB or III colon cancer treated with adjuvant chronomodulated vs standard schedule fluorouracil and leucovorin calcium with or without carboplatin.
  • Compare the overall survival of patients treated with these regimens.
  • Compare the toxicity of these regimens in these patients.
  • Compare the quality of life of patients treated with these regimens.
  • Determine the dose intensities of fluorouracil and carboplatin in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and disease stage (IIB vs III). Patients are randomized to 1 of 4 treatment arms.

  • Arm I (standard schedule): Patients receive fluorouracil (5-FU) IV continuously and leucovorin calcium (CF) IV on days 1 and 2.
  • Arm II (standard + carboplatin schedule): Patients receive 5-FU and CF as in arm I plus carboplatin IV on day 1.
  • Arm III (chronomodulated schedule): Patients receive 5-FU IV continuously and CF IV continuously on days 1-4.
  • Arm IV (chronomodulated + carboplatin schedule): Patients receive 5-FU and CF as in arm III plus carboplatin IV continuously on days 1-4.

Quality of life is assessed.

Treatment in all arms repeats every 14 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 660-800 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon

    • Stage IIB or III (Dukes stage B2 or C)
    • Complete curative resection performed within the past 7 weeks (negative margins)
    • No local or regional relapsed disease
  • Tumor more than 15 cm above the anal margin
  • Carcinoembryonic antigen less than 5 ng/mL (after surgery)
  • No rectal cancer
  • No metastatic disease

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-1 OR
  • Karnofsky 60-100%

Life expectancy

  • Not specified

Hematopoietic

  • Neutrophil count at least 2,000/mm3
  • Platelet count at least 100,000/mm3

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT and SGPT no greater than 5 times ULN

Renal

  • Creatinine no greater than 1.5 times ULN

Cardiovascular

  • No serious coronary disease

Other

  • Not pregnant
  • Fertile patients must use effective contraception
  • No concurrent infectious disease
  • No other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No prior immunotherapy

Chemotherapy

  • No prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy (before or after surgery)

Surgery

  • See Disease Characteristics

Other

  • No concurrent participation in another clinical trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00046995

Locations
Belgium
Centre Hospitalier Hutois Recruiting
Huy, Belgium, 4500
Contact: Jean Bury, MD, PhD     32-85-27-21-11     jean.bury@chh.be    
Clinique Saint-Joseph Recruiting
Liege, Belgium, B 4000
Contact: Christian N.J. Focan, MD, PhD     32-4-224-8990     Christian.Focan@CHC.be    
Sponsors and Collaborators
Groupe Regional d'Etudes du Cancer Colorectal
Investigators
Study Chair: Christian N.J. Focan, MD, PhD Clinique Saint-Joseph
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: CDR0000257228, GRECCR-03, EU-20201
Study First Received: October 3, 2002
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00046995     History of Changes
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the colon
stage II colon cancer
stage III colon cancer

Study placed in the following topic categories:
Antimetabolites
Vitamin B Complex
Digestive System Neoplasms
Immunologic Factors
Gastrointestinal Diseases
Colonic Diseases
Adjuvants, Immunologic
Leucovorin
Trace Elements
Carboplatin
Folinic Acid
Intestinal Diseases
 Immunosuppressive Agents
Rectal Diseases
Intestinal Neoplasms
Calcium, Dietary
Digestive System Diseases
Vitamins
Fluorouracil
Gastrointestinal Neoplasms
Micronutrients
Adenocarcinoma
Colonic Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Gastrointestinal Diseases
Antineoplastic Agents
Colonic Diseases
Physiological Effects of Drugs
Leucovorin
Rectal Diseases
Neoplasms by Site
Vitamins
Therapeutic Uses
Micronutrients
 Digestive System Neoplasms
Vitamin B Complex
Growth Substances
Carboplatin
Intestinal Diseases
Immunosuppressive Agents
Intestinal Neoplasms
Pharmacologic Actions
Neoplasms
Digestive System Diseases
Fluorouracil
Gastrointestinal Neoplasms
Colonic Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services